Companion Diagnostic Testing for Non-Small Cell Lung Cancer

  • ISBN 9780199388646
  • Author: LYMAN
  • Publ Date: 2014-05-08
  • Edition:
  • Binding: Cards

$21.74
Sale: $19.57
Save: 10% off
+ GST

Add to Cart:
Lung cancer is a malignancy of epidemic proportions. In the United States, it is estimated that there will be more than 228,000 new cases of lunch cancer each year, with 40% of those presenting with Stage IV metastatic disease. Non-small cell lung cancers (NSCLC) make up approximately 70% of all lung cancers diagnosed. Ongoing advancements in medicine are raising the bar in oncology management, including NSCLCs. Data show that patients respond differently to the
same drug. By identifying a sub-group of patients most likely to benefit from a specific drug therapy, patients can be confident that their treatment will provide optimal responses. A companion
diagnostic enables personalized healthcare. It is used to predict which patients are most likely to benefit from a particular therapy and/or how best to administer a therapy to an individual. This 6 panel pocket card provides at-a-glance information about companion diagnostic testing for non-small cell lung cancers. The card concisely summarizes: epidemiology; histology; etiology and risk factors; evaluation and staging; treatment overview; personalized treatment; companion testing; and
implications. The content is excerpted from Dr. Gary Lyman's Oxford American Handbook of Oncology.
Whilst every effort is made to keep pricing information up-to-date, prices and availability are subject to change without notice. Where prices or other details have changed from those listed on the website we will contact the customer and only proceed with the order after receiving acceptance of the revised pricing.
Your IP Address is: 18.227.111.30
Copyright © 2024 Medical Books. Powered by Zen Cart